Terminology for drug incidents in the hospital context;Terminologia de incidentes com medicamentos no contexto hospitalar

Cadernos de Saude Publica

Volumn 24, Issue 9, 2008, Pages 1965-1975

  Rissato, Maria De Almeida Rocha ^a   Romano Lieber, Nicolina Silvana ^b   Lieber, Renato Rocha ^c  

^a STATE UNIVERSITY OF MARINGÁ   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

Author keywords

Drugs relations; Medication errors; Pharmaceutical preparations

Indexed keywords

EID: 53149121639     PISSN: 0102311X     EISSN: 16784464     Source Type: Journal    
DOI: 10.1590/s0102-311x2008000900002     Document Type: Review

References (70)

1. Otero MJ, Dominguez-Gil A. Acontecimientos adversos por medicamentos: una patologia emergente. Farm Hosp 2000; 24:258-66.
2. Anacleto TA, Perini E, Rosa MB, César CC. Medication errors and drug-dispensing sytems in a hospital pharmacy. Clinics 2005; 60:325-32.
3. Classen DC. Medical safety: moving from illusion to reality [Editorial]. JAMA 2003; 289:1154-6.
4. Jonhson JA, Bootman JL. Drug-related morbidity and mortality. A cost-of-illness model. Arch Intern Med 1995; 155:1949-56.
5. Bates DW, Spell N, Cullen DJ, Burdick E, Laird N, Petersen LA, et al. The costs of adverse drug events in hospitalized patients. Adverse Drug Events Prevention Study Group. JAMA 1997; 277:307-11.
6. World Health Organization. International classification for patient safety (ICPS). http://www.who-icps.org/ (acessado em 23/Jan/2008).
7. World Health Organization. WHO draft guidelines for adverse event reporting and learning systems - from information to action; 2005. http://who.int/patientsafety/events/05/Reporting_Guidelines.pdf (acessado em 21/Jan/2008).
8. Ross S. Drug-related adverse events: a readers' guide to assessing literature reviews and meta-analyses. Arch Intern Med 2001; 161:1041-6.
9. Winterstein AG, Sauer BC, Hepler CD, Poole C. Preventable drug-related hospital admissions. Ann Pharmacother 2002; 36:1238-48.
10. Rosa MBR, Perini E. Erros de medicação: quem foi? Rev Assoc Med Bras 2003; 49:335-41.
11. Nebeker JR, Barach P, Samore MH. Clarifying adverse drug events: a clinician's guide to terminology, documentation, and reporting. Ann Intern Med 2004; 140:795-801.
12. Agência Nacional de Vigilância Sanitária. Conceitos de farmacovigilância. http://www.anvisa.gov.br/farmacovigilancia/ conceito_glossario.htm# (acessado em 19/Jan/2008).
13. World Health Organization. International drug monitoring: the role of national centers. Geneva: World Health Organization; 1972. (WHO Technical Reports Series, 498).
14. Committee of Experts on Management of Safety and Quality in Health Care - Expert Group on Safe Medication Practices. Glossary of terms related to patient and medication safety. http://www.who.int/patientsafety/highlights/ COE_patient_and_medication_safety_gl.pdf (acessado em 21/Jan/2008).
15. Pharmaceutical Care Network Europe Foundation. Classification for drug related problems. http://www.pcne.org (acessado em 01/Out/2006).
16. American System Health Pharmacy. ASHP statement on pharmaceutical care. Am J Hosp Pharm 1993; 50:1720-3.
17. Hepler CD, Strand LM. Opportunities and responsibilities in pharmaceutical care. Am J Hosp Pharm 1990; 47:533-43.
18. Cipolle RJ, Strand LM, Morley PC. El ejercicio de la atención farmacéutica. Madrid: McGraw-Hill Interamericana; 2000.
19. Comité de Consenso. Segundo consenso de Granada sobre problemas relacionados con medicamentos. Ars Pharm 2002; 43:179-87.
20. Ivama AM, Noblat L, Castro MS, Jamarillo NM, Oliveira NVBV, Rech N. Atenção farmacêutica no Brasil: trilhando caminhos - relatório 2001-2002. Brasília: Organização Pan-Americana da Saúde; 2002.
21. Van Den Bemt PMLA, Egberts TCG, Lenderink AW, Verzijl JM, Simons KA, Van der Pol WS, et al. Risk factors for the development of adverse drug events in hospitalized patients. Pharm World Sci 2000; 22:62-6.
22. Classen DC, Pestotnik SL, Evans S, Lloyd JF, Burke JP. Adverse drug events in hospitalized patients: excess length of stay, extra cost, and attributable mortality. JAMA 1997; 277:301-6.
23. Evans RS, Pestotnik SL, Classen DC, Horn SD, Bass SB, Burke JP. Preventing adverse drug events in hospitalized patients. Ann Pharmacother 1994; 28:523-7.
24. Rozich JD, Haraden CR, Resar RK. Adverse drug event trigger tool: a practical methodology for measuring medication related harm. Qual Saf Health Care 2003; 12:194-200.
25. World Health Organization. Glossary of terms used in Pharmacovigilance. http://www.who-umc.org/graphics/8321.pdf (acessado em 01/Out/2006).
26. Brennan TA, Leape LL, Laird NM, Herbert L, Locadio AR, Lawthers AG, et al. Incidence of adverse events and negligence in hospitalized patients. Results of the Harvard Medical Practice Study I. N Engl J Med 1991; 324:370-6.
27. Leape LL, Brennan TA, Laird N, Lawthers AG, Localio AR, Barnes BA, et al. The nature of adverse events in hospitalized patients. Results of the Harvard Medical Practice Study II. N Engl J Med 1991; 324:377-84.
28. Bates DW, Leape LL, Petrycki S. Incidence and preventability of adverse drug events in hospitalized adults. J Gen Intern Med 1993; 8:289-94.
29. Bates DW, Cullen DJ, Laird N, Petersen L, Small SD, Servi D, et al. Incidence of adverse drug events and potential adverse drug events. Implications for prevention. JAMA 1995; 274:29-33.
30. Van Den Bemt PMLA, Egberts TCG, Jong-van den Berg LTW, Brouwers JRBJ. Drug-related problems in hospitalized patients. Drug Saf 2000; 22:321-33.
31. Leape LL, Bates DW, Cullen DJ, Cooper J, Demonaco HJ, Gallivan T, et al. System analysis of adverse drug events. JAMA 1995; 274:35-43.
32. Rothschild J, Frank FA, Gandhi TK, Kaushal R, Williams DH, Bates DW. Analysis of medication-related malpractice claims: causes, preventability and costs. Arch Intern Med 2002; 162:2414-20.
33. Gandhi TK, Seger DL, Bates DW. Identifying drug safety issues: from research to practice. Int J Qual Health Care 2000; 12:69-79.
34. Gandhi TK, Weingart SN, Borus J, Seger AC, Peterson J, Burdick E, et al. Adverse drug events in ambulatory care. N Engl J Med 2003; 348:1556-64.
35. Hope C, Overhage JM, Seger A, Teal E, Mills V, Fiskio J, et al. A tiered approach is more cost effective than traditional pharmacist-based review for classifying computer-detected signal as adverse drug events. J Biomed Inform 2003; 36:92-8.
36. Hardmeier B, Braunschweig S, Cavallaro M, Roos M, Pauli-Magnus C, Giger M, et al. Adverse drug events caused by medication errors in medical inpatients. Swiss Med Wkly 2004; 134:664-70.
37. a Ed. Rio de Janeiro: Editora Nova Fronteira; 1982.
38. Lieber RR, Romano-Lieber NS. O conceito de risco: Janus reinventado. In: Minayo MCS, Miranda AC, organizadores. Saúde e ambiente sustentável: estreitando nós. Rio de Janeiro: Editora Fiocruz; 2002. p. 69-111.
39. Van Mill JWF, Westerlund T, Hersberger KE, Schaefer MA. Drug-related problem classification systems. Ann Pharmacother 2004; 38:859-67.
40. American System Health Pharmacy. Suggested definitions and relationships among medication misadventures, medication errors, adverse drug events, and adverse drug reactions. Am J Health Syst Pharm 1998; 55:165-6.
41. Schneider P, Gift MG, Lee YP, Rothermich E, Sill BE. Cost of medication-related problems at a university hospital. Am J Health Syst Pharm 1995; 52:2415-8.
42. Major S, Bard S, Bahlawan L, Hassan G, Khogaoghlanian T, Khalil R, et al. Drug-related hospitalization at a tertiary teaching center in Lebanon: incidence, associations, and relation to self-medicating behavior. Clin Pharmcol Ther 1998; 64:450-61.
43. Roughead E, Gilbert AL, Primrose JG, Sanson LN. Coding drug-related hospital admissions in medical records: is it adequate for monitoring the quality of medication use? Aust J Hosp Pharm 1998; 28:7-12.
44. Roughead E, Gilbert AL, Primrose JG, Sanson LN. Drug-related hospital admissions. Med J Aust 1998; 168:405-8.
45. Van Den Bemt PMLA, Egberts TCG, Lenderink AW, Verzijl JM, Simons KA, Van der Pol WS, et al. Adverse drug events in hospitalized patients. A comparison of doctors, nurses and patients as sources of reports. Eur J Clin Pharmacol 1999; 55:155-8.
46. Raschetti R, Norgutti M, Mennitti-Ippolito F. Suspected adverse drug events requering emergency department visits or hospital admissions. Eur J Clin Pharmacol 1999; 54:959-63.
47. William K. Potential risks and prevention, part 4: reports of significant adverse drug events. Am J Health Syst Pharm 2001; 58:1406-12.
48. Hernández PA, López MJO, Fernández JAM. Ingresos hospitalarios causados por medicamentos: incidencia, características y coste. Farm Hosp 2002; 26:77-89.
49. Martín MT, Codina C, Tuset M, Carné X, Nogué S, Ribas J. Problemas relacionados con la medicación como causa del ingreso hospitalario. Med Clin (Barc) 2002; 118:205-10.
50. Ruciman WB, Roughead E, Semple SJ, Adams R. Adverse drug events and medication errors in Australia. Int J Qual Health Care 2003; 15 Suppl 1:i49-59.
51. Kanjanarat P, Winterstein AG, Johns TE, Hatton RC, Gonzalez-Rothi R, Segal R. Nature of preventable adverse drug events in hosptitals: a literature review. Am J Health Syst Pharm 2003; 60:1750-8.
52. Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis and management. Lancet 2000; 356:1255-9.
53. Karch FE, Lasagna L. Adverse drug reactions: a critical review. JAMA 1975; 234:1236-41.
54. American System Health Pharmacy. ASHP guidelines on adverse drug reaction monitoring and reporting. Am J Hosp Pharm 1995; 52:417-9.
55. Meyboon RHB, Lindquist M, Egbersts ACG. An ABC of drug-related problems. Drug Saf 2000; 22:415-23.
56. Fernícola NAGG, Jauge P. Nociones básicas de toxicología. México DF: Centro Panamericano de Ecología Humana y Salud, Organización Panamericana de la Salud; 1985. p. 56.
57. Fernández-Llimós F, Faus MJ. From "drug related problems" to "negative clinical outcomes". Am J Health Syst Pharm 2005; 62:2348-50.
58. Winterstein AG, Hatton RC, Gonzalez-Rothi R, Johns TE, Segal R. Identifying clinically significant preventable adverse drug events through a hospital's database of adverse drug reaction reports. Am J Health Syst Pharm 2002; 59:1742-9.
59. Senst BL, Achusim LE, Genest RP, Cosentino LA, Ford CC, Little JA, et al. Practical approach to determining cost and frequency of adverse drug events in a health care network. Am J Health Syst Pharm 2001; 58:1126-32.
60. Corral-Baena S, Guerrero-Aznar MD, Beltrán-García M, Salas-Turrens J. Utilización del CMBD como herramienta para la detección de acontecimientos adversos a medicamentos. Farm Hosp 2004; 28:258-65.
61. Forster AJ, Halil RB, Tierney MG. Pharmacist surveillance of adverse drug events. Am J Health Syst Pharm 2004; 61:1466-72.
62. Correr CJ. Os problemas relacionados aos medicamentos no contexto da atenção farmacêutica: uma avaliação de conceitos. Pharm Bras 2002; 32:73-8.
63. Bates DW, Boyle DL, Vander-Vliet MB, Schneider J, Leape L. Relationship between medication errors and adverse drug events. J Gen Intern Med 1995; 10:199-205.
64. Kvasz M, Allen E, Gordon M, Ro EY, Estok R, Olkin I, et al. Adverse drug reactions in hospitalized patients: a critique of a meta-analysis. Med Gen Med 2000; 2:E3.
65. Kucukarslan SN, Peters M, Mlynarek M, Nafziger DA. Pharmacists on rounding teams reduce preventable adverse drug events in hospital general medicine units. Arch Intern Med 2003; 163:2014-8.
66. Von Laue NC, Schwappach DLB, Koeck CM. The epidemiology of preventable adverse drug events: a review of the literature. Wien Klin Wochenschr 2003; 115:407-15.
67. Otero MJ, Schmitt E. Clarifying terminology for adverse drug events. Ann Intern Med 2005; 142:77-9.
68. Nebeker JR, Samore MH, Barach P. Clarifying terminology for adverse drug events. Ann Intern Med 2005; 142:79-80.
69. Bogner MS. Human error in medicine. Hillsdale: Lawrence Erlbaum Associates; 1994.
70. Mendes W, Travassos C, Martins M, Marques PM. Adaptação dos instrumentos de avaliação de eventos adversos para uso em hospitais brasileiros. Rev Bras Epidemiol 2008; 11:55-66.